Clinical Trial Update: Pembrolizumab in Treating Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in patients with recurrent glioblastoma (and recurrent gliosarcoma) has results posted, with the study currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-01-11